Cargando…

Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?

Nonalcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and affects a considerable proportion of the general population worldwide. Obesity is a major risk factor for development and progression of NAFLD and weight loss is an effective intervention for the management of NAFLD....

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsankof, Alexandra, Neokosmidis, Georgios, Koureta, Evgenia, Veneti, Stavroula, Cholongitas, Evangelos, Tziomalos, Konstantinos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478023/ https://www.ncbi.nlm.nih.gov/pubmed/36120448 http://dx.doi.org/10.3389/fendo.2022.984041

Ejemplares similares

Combination therapies in nonalcoholic fatty liver disease using antidiabetic and disease-specific drugs
por: Koureta, Evgenia, et al.
Publicado: (2023)

Role of cenicriviroc in the management of nonalcoholic fatty liver disease
por: Neokosmidis, Georgios, et al.
Publicado: (2018)

Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?
por: Neokosmidis, Georgios, et al.
Publicado: (2021)

Adiponectin: A player in the pathogenesis of hormone-dependent cancers
por: Tsankof, Alexandra, et al.
Publicado: (2022)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

Considerations for management of patients with diabetes mellitus and acute COVID-19
por: Mougakou, Efterpi, et al.
Publicado: (2022)

Alcohol consumption in patients with nonalcoholic fatty liver disease: yes, or no?
por: Protopapas, Adonis A., et al.
Publicado: (2021)

Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management
por: Chrysavgis, Lampros, et al.
Publicado: (2020)

Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
por: Veneti, Stavroula, et al.
Publicado: (2020)

The Role of Finerenone in the Management of Diabetic Nephropathy
por: Veneti, Stavroula, et al.
Publicado: (2021)

The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke
por: Tsankof, Alexandra, et al.
Publicado: (2021)

Novel insights in the prevention of perinatal transmission of hepatitis B
por: Tziomalos, Konstantinos, et al.
Publicado: (2018)

Effects of Lifestyle Measures, Antiobesity Agents, and Bariatric Surgery on Serological Markers of Inflammation in Obese Patients
por: Tziomalos, Konstantinos, et al.
Publicado: (2010)

Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
por: Sofogianni, Areti, et al.
Publicado: (2020)

Associations between nonalcoholic fatty liver disease and ischemic stroke
por: Alkagiet, Stelina, et al.
Publicado: (2018)

Frailty in metabolic syndrome, focusing on nonalcoholic fatty liver disease
por: Karakousis, Nikolaos D., et al.
Publicado: (2022)

Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease
por: Kontana, Anastasia, et al.
Publicado: (2019)

Lean nonalcoholic fatty liver disease and sarcopenia
por: Chen, Milian, et al.
Publicado: (2023)

Plants' Metabolites as Potential Antiobesity Agents
por: Gooda Sahib, Najla, et al.
Publicado: (2012)

Obesity and Outcome of Assisted Reproduction in Patients With Polycystic Ovary Syndrome
por: Tziomalos, Konstantinos, et al.
Publicado: (2018)

Role of extracellular vesicles in nonalcoholic fatty liver disease
por: Jiang, Wei, et al.
Publicado: (2023)

Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
por: Yang, Bing, et al.
Publicado: (2022)

Corrigendum: Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
por: Yang, Bing, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease in University Rugby Football Players
por: Nirengi, Shinsuke, et al.
Publicado: (2018)

The impact of obstructive sleep apnea on nonalcoholic fatty liver disease
por: Tang, Haiying, et al.
Publicado: (2023)

A Drosophila Model for Screening Antiobesity Agents
por: Men, Tran Thanh, et al.
Publicado: (2016)

Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease
por: Zhou, Fangli, et al.
Publicado: (2021)

Clinical characterization and proteomic profiling of lean nonalcoholic fatty liver disease
por: Jiang, Yuanye, et al.
Publicado: (2023)

Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis
por: Cholongitas, Evangelos, et al.
Publicado: (2021)

Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms
por: Takahashi, Hirokazu, et al.
Publicado: (2018)

Complex impacts of gallstone disease on metabolic syndrome and nonalcoholic fatty liver disease
por: Lyu, Jingting, et al.
Publicado: (2022)

Editorial: With obesity becoming the new normal, what should we do? ‐Volume II
por: Tziomalos, Konstantinos, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population
por: Ciardullo, Stefano, et al.
Publicado: (2021)

Red Blood Cell Count: An Unrecognized Risk Factor for Nonalcoholic Fatty Liver Disease
por: Zhong, Fang, et al.
Publicado: (2021)

Clinical spectrum transition and prediction model of nonalcoholic fatty liver disease in children with obesity
por: Zhou, Xuelian, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease is specifically related to the risk of hepatocellular cancer but not extrahepatic malignancies
por: Albhaisi, Somaya, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease and type 2 diabetes: an observational and Mendelian randomization study
por: Yu, Yuetian, et al.
Publicado: (2023)

Structure-Based Optimization and Biological Evaluation of Pancreatic Lipase Inhibitors as Novel Potential Antiobesity Agents
por: Wei, Kun, et al.
Publicado: (2015)

Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Zhang, Yuyuan, et al.
Publicado: (2022)

Peptides and Peptidomimetics as Potential Antiobesity Agents: Overview of Current Status
por: Kumar, Maushmi S.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h4j71u0do83c87kgip2crq5f9n